Olaparib
Treatment for Ovarian Cancer
Typical Dosage: 300 mg twice daily
Effectiveness
78%
Safety Score
50%
Clinical Trials
143
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg twice daily
Time to Effect
1-3 months
Treatment Duration
2-3 years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$360,000
Monitoring:$6,000
Side Effect Mgmt:$3,000
Total Annual:$369,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
2.7
Outcome-Based Costs
Cost per Responder
$527,143
Cost per Remission
$1,230,000
Comparison vs Carboplatin + Paclitaxel (chemotherapy alone)
Cost Difference
+$349,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
3 active trials recruiting for Olaparib in Ovarian Cancer
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT06121401ACTIVE NOT RECRUITINGPHASE4
190 participants
INTERVENTIONAL
San Fermo della Battaglia, Italy +1 more
Started: Sep 15, 2023
Selumetinib and Olaparib in Solid Tumors
NCT03162627ACTIVE NOT RECRUITINGPHASE1
90 participants
INTERVENTIONAL
Houston, United States
Started: Aug 4, 2017
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
NCT04644289RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Mannheim, Germany +5 more
Started: May 5, 2022
Completed Clinical Trials
10 completed trials for Olaparib in Ovarian Cancer
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
NCT00494442COMPLETEDPHASE2
58 participants
INTERVENTIONAL
Los Angeles, United States +10 more
Started: Jun 11, 2007
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941COMPLETED
130 participants
OBSERVATIONAL
Angers, France +27 more
Started: Oct 11, 2018
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
NCT04532645COMPLETED
342 participants
OBSERVATIONAL
Avignon, France +54 more
Started: Jan 7, 2021
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
NCT00628251COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Los Angeles, United States +23 more
Started: Jul 30, 2008
PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
NCT04041128COMPLETEDEARLY_PHASE1
14 participants
INTERVENTIONAL
Dallas, United States
Started: Jul 23, 2019
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
NCT00679783COMPLETEDPHASE2
99 participants
INTERVENTIONAL
Edmonton, Canada +5 more
Started: Jul 8, 2008
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
NCT03106987COMPLETEDPHASE3
220 participants
INTERVENTIONAL
Leuven, Belgium +81 more
Started: Jun 8, 2017
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
NCT01078662COMPLETEDPHASE2
298 participants
INTERVENTIONAL
West Hollywood, United States +13 more
Started: Feb 21, 2010
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
NCT03470805COMPLETEDPHASE2
9 participants
INTERVENTIONAL
Badalona, Spain +15 more
Started: Jun 21, 2018
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
NCT03314740COMPLETEDPHASE2
123 participants
INTERVENTIONAL
Brescia, Italy +5 more
Started: Jun 12, 2017
Showing 20 of 143 total trials